(1)
PRESS RELEASE
Nyxoah announces the publication of first positive clinical data in an OSA patient suffering from Complete Concentric Collapse (CCC)
Mont-Saint-Guibert, Belgium - 3
rd March 2021 - Nyxoah SA (Euronext: NYXH) ( Nyxoah or the Company ), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the publication of an article presenting the first case of successful treatment of an OSA patient suffering from Complete Concentric Collapse (CCC) with Nyxoah s unique Genio bilateral neurostimulation solution
1.
Patients suffering from Complete Concentric Collapse (CCC) currently amount for at least 30% of the existing OSA patient population. For now, these patients are contra-indicated for existing Hypoglossal Nerve Stimulation OSA therapies. Nyxoah is currently conducting the BETTER SLEEP study, that aims to assess the effectiveness of the Genio system bila
PRESS RELEASE
Nyxoah announces the publication of first positive clinical data in an OSA patient suffering from Complete Concentric Collapse (CCC)
Mont-Saint-Guibert, Belgium – 3
rd March 2021 – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the publication of an article presenting the first case of successful treatment of an OSA patient suffering from Complete Concentric Collapse (CCC) with Nyxoah’s unique Genio® bilateral neurostimulation solution
1.
Patients suffering from Complete Concentric Collapse (CCC) currently amount for at least 30% of the existing OSA patient population. For now, these patients are contra-indicated for existing Hypoglossal Nerve Stimulation OSA therapies. Nyxoah is currently conducting the BETTER SLEEP study, that aims to assess the effectiveness of the Genio�